Citations 2
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dobelbower, M.C., Gettinger, Scott , Govindan, Ramaswamy , Gubens, Matthew A. , Hennon, Mark, Horn, Leora , Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Loo, Billy W. , Martins, Renato , Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Stevenson, James, Swanson, Scott J. , Tauer, Kurt W., Yang, Stephen C. , Gregory, Kristina M., OCN, Hughes, Miranda, Schild, Steven E. , Loo, Billy W , Govindan, Ramaswamy , Aggarwal, Charu , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Reckamp, Karen L. , OCN, Hughes, Miranda
Journal of the National Comprehensive Cancer Network | December 5, 2019 | Volume: 17 | Issue: 12 | Pages: 1464-1472
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates in immunotherapy. For the 2020 update, all of the systemic therapy regimens have been categorized using a new preference stratification system; certain regimens are now recommended as “preferred interventions,” whereas others are categorized as either “other recommended interventions” or “useful under certain circumstances.”